GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inhibikase Therapeutics Inc (NAS:IKT) » Definitions » Cash Receipts from Tax Refunds

IKT (Inhibikase Therapeutics) Cash Receipts from Tax Refunds


View and export this data going back to 2020. Start your Free Trial

What is Inhibikase Therapeutics Cash Receipts from Tax Refunds?

Cash Receipts from Tax Refunds only applicable to companies reporting Cash Flow from Operations in direct method.


Inhibikase Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
3350 Riverwood Parkway SE, Suite 1900, Atlanta, GA, USA, 30339
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
Executives
Paul C Grint director 7757 DOUGHILL COURT, SAN DIEGO CA 92127
Dennis N Berman director 9605 SCRANTON RD, STE 240, SAN DIEGO CA 92121
Roy Lester Freeman director 256 SUMMIT AVE, BROOKLINE MA 02446
Gisele Dion director C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538
Milton H. Werner director, 10 percent owner, officer: President and CEO 3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA GA 30339
Joseph Frattaroli officer: Cheif Financial Officer
Elizabeth G. O'farrell director 932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
Daniel Kalman 10 percent owner 3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA GA 30339